Semperit Holding Q1 2024: Stable Revenue and Impressive 9% EBITDA Growth

• Semperit AG Holding reported stable revenue of EUR 176.0 million and a 9% increase in EBITDA in Q1 2024.
• Cost reductions initiated in the previous year reduced expenses by EUR 9.9 million, with EUR 4.1 million attributable to Q1 2024.
• The company confirmed its EBITDA guidance of around EUR 80 million for the year.
• Semperit is nearing the final closing of the sale of its remaining medical business, with a co-use agreement concluded with Harps in March 2024.
• The company has a robust financial base with an equity ratio of 45.1%, net financial debt of EUR 120.2 million, and cash and cash equivalents of EUR 119.9 million.
• Earnings after tax improved to EUR 3.6 million, with earnings after tax from continued operations at EUR 5.0 million.

The next important date, Quarterly report, at Semperit Holding is on 08.08.2024.

The price of Semperit Holding at the time of the news was 11,500EUR and did not change compared to the previous day.
22 minutes after the article was published, the price was 11,490EUR this corresponds to a minus of -0,09 % since publication.

Semperit Holding

-0,51 %

-1,19 %

+0,69 %

-13,37 %

-42,98 %

-68,91 %

-10,45 %

-72,02 %

-14,56 %

ISIN:AT0000785555WKN:870378

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max